James Treace - Oct 19, 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for James T. Treace
Stock symbol
TMCI
Transactions as of
Oct 19, 2022
Transactions value $
-$1,141,819
Form type
4
Date filed
10/21/2022, 08:00 PM
Previous filing
Sep 16, 2022
Next filing
Mar 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$687K -30.4K -2.67% $22.59 1.11M Oct 19, 2022 Direct F1, F2
transaction TMCI Common Stock Sale -$254K -10.9K -0.98% $23.37 1.1M Oct 19, 2022 Direct F1, F3
transaction TMCI Common Stock Sale -$201K -8.74K -0.8% $23.02 1.09M Oct 20, 2022 Direct F1, F4
holding TMCI Common Stock 556K Oct 19, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.1600 to $23.1200 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.2600 to $24.1900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.5000 to $23.3800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.